ArticleFrontiers in nutrition2025
Association of unsaturated fatty acid intake with risk of all-cause death in patients with osteoarthritis.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Omega-3 PUFAs in musculoskeletal health and sports medicine: from molecular pathways to precision nutrition strategies.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To investigate the relationship between unsaturated fatty acids (UFAs) intake and the risk of all-cause mortality in osteoarthritis (OA) patients. Methods: This cohort study included the data of 3,271 participants with OA using data from the National Health and Nutrition Examination Survey (NHANES). Univariate and multivariable weighted Cox regression models were applied to analyze the relationship between UFAs intake and the risk of mortality in patients with OA. Subgroup analysis was used in age, gender, cardiovascular disease (CVD), hypertension, and diabetes. Hazard ratio (HR), and 95% confidence interval (CI) were calculated. Results: The median follow-up time was 38.00 (69.00, 104.00) months, with 2,670 participants survived and 601 died. Monounsaturated fatty acids (MUFAs) ≥31.30 was associated with reduced risk of all-cause mortality in OA patients (HR = 0.48, 95% CI: 0.32-0.73). Lowered risk of all-cause mortality in OA patients was observed in patients with octadecenoic acid ≥29.14 (HR = 0.50, 95% CI: 0.34-0.72). Eicosenoic acid of 0.15-0.30 (HR = 0.70, 95% CI: 0.55-0.90) or eicosenoic acid ≥0.30 (HR = 0.62, 95% CI: 0.46-0.84) was related to decreased risk of all-cause mortality in OA patients. Polyunsaturated fatty acids (PUFAs) ≥20.33 was associated with reduced risk of all-cause mortality in OA patients (HR = 0.72, 95% CI: 0.54-0.96). Omega-3 fatty acid ≥1.98 was correlated with decreased risk of all-cause mortality in OA patients (HR = 0.60, 95% CI: 0.45-0.81). Decreased risk of all-cause mortality was found in people with alpha-linolenic acid (ALA) of 1.00-1.83 (HR = 0.75, 95% CI: 0.59-0.96) or ALA ≥1.83 (HR = 0.65, 95% CI: 0.46-0.92) in OA patients. Omega-6 fatty acid ≥18.04 (HR = 0.68, 95% CI: 0.51-0.92) or linoleic acid ≥17.89 (HR = 0.67, 95% CI: 0.50-0.90) were related to decreased risk of all-cause mortality in people with OA. Conclusion: Total MUFAs and PUFAs, octadecenoic acid, eicosenoic acid, omega-3 fatty acid, ALA, omega-6 fatty acid and linoleic acid were correlated with decreased risk of all-cause mortality in OA patients, which might suggest the importance of specific UFAs supplement in OA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.